Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274]
Corresponding Author of This Article
Danijel Galun, Associate Professor, Clinic of Digestive Surgery, University Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia. galun95@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Sep 18, 2015; 7(20): 2274-2291 Published online Sep 18, 2015. doi: 10.4254/wjh.v7.i20.2274
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols
Danijel Galun, Dragan Basaric, Marinko Zuvela, Predrag Bulajic, Aleksandar Bogdanovic, Nemanja Bidzic, Miroslav Milicevic
Danijel Galun, Dragan Basaric, Marinko Zuvela, Predrag Bulajic, Aleksandar Bogdanovic, Nemanja Bidzic, Miroslav Milicevic, Clinic of Digestive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia
Danijel Galun, Marinko Zuvela, Miroslav Milicevic, Medical School, University of Belgrade, 11000 Belgrade, Serbia
Author contributions: Galun D and Milicevic M designed research; Galun D, Basaric D and Zuvela M performed research; Bulajic P, Bogdanovic A and Bidzic N analyzed data; Galun D and Milicevic M wrote the paper.
Conflict-of-interest statement: The authors state no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Danijel Galun, Associate Professor, Clinic of Digestive Surgery, University Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia. galun95@gmail.com
Telephone: +381-11-3615652 Fax: +381-11-3615655
Received: August 29, 2014 Peer-review started: August 30, 2014 First decision: November 14, 2014 Revised: July 6, 2015 Accepted: August 30, 2015 Article in press: August 31, 2015 Published online: September 18, 2015
Core Tip
Core tip: In response to the hepatocellular carcinoma (HCC) burden marked differences between countries are reflected in providing disparate quality of healthcare considering screening and surveillance programs; available treatment modalities and drugs; reimbursement of specific treatment options by the state-funded health insurance. Since the number of new HCC cases being diagnosed each year is nearly equal to the number of deaths from this cancer it is clear that the international scientific community and healthcare systems worldwide have no efficient answer to this problem. International consensus on the use of any given staging model is lacking. High-quality trials with better patients’ stratification are mandatory. This review article reflects the perspective of liver surgeons working in a developing country.
